Literature DB >> 20731577

Outpatient parenteral antimicrobial therapy today.

Joseph A Paladino1, Donald Poretz.   

Abstract

Since its introduction in the 1970s, outpatient parenteral antimicrobial therapy (OPAT) has become a standard modality for patients with many infections requiring long-term intravenous antibiotic therapy. Delivery of OPAT may occur in physicians' offices, hospital clinics, specialized infusion centers, and currently most often, patient's homes, often self-administered. Patients are selected for OPAT by physicians familiar with both the course of their infections, their personal suitability for outpatient care, and the availability of reimbursement. OPAT is reportedly safe, effective, practical, and cost-effective. An OPAT Outcomes Registry contains information from >11,000 antibiotic courses administered from 1997 through 2000. Although a number of studies are purported to analyze the economic impact of OPAT on health care, a comprehensive, clinical outcomes-based pharmacoeconomic analysis, as described here, has, to our knowledge, yet to be done.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731577     DOI: 10.1086/653520

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  62 in total

1.  A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.

Authors:  Brent W Wieland; Jodie R Marcantoni; Kerry M Bommarito; David K Warren; Jonas Marschall
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

2.  What Medicare Is Missing.

Authors:  Sara Keller; Peter Pronovost; Sara Cosgrove
Journal:  Clin Infect Dis       Date:  2015-09-03       Impact factor: 9.079

3.  Safety and effectiveness of home intravenous antibiotic therapy for multidrug-resistant bacterial infections.

Authors:  A Mujal; J Sola; M Hernandez; M-A Villarino; M-L Machado; M Baylina; J Tajan; J Oristrell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-06       Impact factor: 3.267

4.  Outpatient parenteral antibiotic therapy in an academic practice in Rhode Island.

Authors:  Francine Touzard Romo; Brian Resnick; Mildred Perez-Cioe; Timothy P Flanigan; Erna M Kojic; Curt G Beckwith
Journal:  R I Med J (2013)       Date:  2014-01-05

5.  Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.

Authors:  Kimberly G Blumenthal; Ilan Youngster; Erica S Shenoy; Aleena Banerji; Sandra B Nelson
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

6.  Outpatient parenteral antimicrobial therapy.

Authors:  Kevin B Laupland; Louis Valiquette
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

7.  Practical considerations in the use of outpatient antimicrobial therapy for musculoskeletal infections.

Authors:  Camelia E Marculescu; Elie F Berbari; J Robert Cantey; Douglas R Osmon
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

8.  The Impact of an Infectious Diseases Transition Service on the Care of Outpatients on Parenteral Antimicrobial Therapy.

Authors:  Sara C Keller; Danielle Ciuffetelli; Warren Bilker; Anne Norris; Daniel Timko; Alex Rosen; Jennifer S Myers; Janet Hines; Joshua Metlay
Journal:  J Pharm Technol       Date:  2013-10

9.  Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit.

Authors:  Courtney A Gidengil; Charlene Gay; Susan S Huang; Richard Platt; Deborah Yokoe; Grace M Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2015-01       Impact factor: 3.254

Review 10.  Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?

Authors:  Ester Steffens; Charlotte Quintens; Inge Derdelinckx; Willy E Peetermans; Johan Van Eldere; Isabel Spriet; Annette Schuermans
Journal:  Infection       Date:  2018-11-15       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.